PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling
DOI:
https://doi.org/10.18433/jpps30626Abstract
Background: Although previous studies demonstrated an anticancer effect for the ligands of peroxisome proliferator-activated receptor gamma (PPARγ) through activation of its anti-inflammatory responses, nevertheless the anti-tumor mechanism of PPARγ has not been intensively investigated. One of the molecules involved in cancer progression is toll-like receptor 4 (TLR4).
Methods: B16F10 melanoma cells were cultured with or without LPS for 24 hr. The cells were subcutaneously injected to two groups of C57BL/6 mice. After the development of palpable tumors each group of animals were divide to four sub-groups and received pioglitazone in different dose ranges (0,10,50,100 mg/kg/day) for 10 days. At the end of the study, the expression of Tlr4, Myd-88, Nf-kb1 genes was evaluated by qRT-PCR in different groups in mice tumor. The TLR-4 protein expression was evaluated by IHC. TNF-α level in mice tumor and serum were measured by ELISA kits. Tumor volume was measured with Vernier calipers.
Results: We observed that activation of PPARγ by its agonist, pioglitazone, reduces tumor volume, Tlr-4, Myd-88, Nf-kb1 mRNA expression, TLR4 protein expression and TNF-α production in melanoma tumor especially in groups that were injected with LPS –stimulated cells. Moreover, treatment of melanoma cells with pioglitazone showed that the inhibitory effects of pioglitazone on LPS-induced inflammatory responses were TLR4 dependent.
Conclusions: The results indicate that pioglitazone, a PPARγ agonist, has a beneficial protective effect against melanoma via interfering with the TLR4-dependent signaling pathways.
Downloads
References
Shcheblyakov D V, Logunov DY, Tukhvatulin AI, Shmarov MM, Naroditsky BS, Gintsburg AL. Toll-Like Receptors (TLRs): The Role in Tumor Progression. Acta naturae . 2010 Jul;2(3):21–9.
Shi M, Chen X, Ye K, Yao Y, Li Y. Application potential of toll-like receptors in cancer immunotherapy: Systematic review. Medicine . 2016 Jun;95(25):e3951. doi: 10.1097/MD.0000000000003951
Burns EM, Yusuf N. Toll-like receptors and skin cancer. Frontiers in immunology . 2014;5:135. doi: 10.3389/fimmu.2014.00135
Mittal D, Saccheri F, Vénéreau E, Pusterla T, Bianchi ME, Rescigno M. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. The EMBO journal . 2010 Jul 7;29(13):2242–52. doi: 10.1038/emboj.2010.94
Dana N, Javanmard SH, Vaseghi G. Effect of lipopolysaccharide on toll-like receptor-4 signals in mouse cancer cells. Bratislavske lekarske listy . 2017;118(10):598–601. doi: 10.4149/BLL_2017_115
Ji Y, Liu J, Wang Z, Li Z. PPARγ agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway. Cytokine . 2011 Sep;55(3):409–19. doi: 10.1016/j.cyto.2011.05.020
Katerinaki E, Evans GS, Lorigan PC, MacNeil S. TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. British journal of cancer . 2003 Sep 15;89(6):1123–9. doi: 10.1038/sj.bjc.6601257
Mössner R, Schulz U, Krüger U, Middel P, Schinner S, Füzesi L, et al. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. The Journal of investigative dermatology . 2002 Sep;119(3):576–82. doi: 10.1046/j.1523-1747.2002.01861.x
Grabacka M, Placha W, Urbanska K, Laidler P, Płonka PM, Reiss K. PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91. Pigment cell & melanoma research . 2008 Jun;21(3):388–96. doi: 10.1111/j.1755-148X.2008.00460.x
Costa V, Foti D, Paonessa F, Chiefari E, Palaia L, Brunetti G, et al. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists. Endocrine-related cancer . 2008 Mar;15(1):325–35. doi: 10.1677/ERC-07-0226
Dana N, Javanmard SH, Rafiee L. Role of peroxisome proliferator-activated receptor alpha and gamma in antiangiogenic effect of pomegranate peel extract. Iranian journal of basic medical sciences . 2016 Jan;19(1):106–10.
Kaplan J, Nowell M, Chima R, Zingarelli B. Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis. Innate immunity . 2014 Jul;20(5):519–28. doi: 10.1177/1753425913501565
Dana N, Vaseghi G, Haghjooy Javanmard S. Crosstalk between Peroxisome Proliferator-Activated Receptors and Toll-Like Receptors: A Systematic Review. Advanced pharmaceutical bulletin . 2019 Feb;9(1):12–21. doi: 10.15171/apb.2019.003
Necela BM, Su W, Thompson EA. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in macrophages. Immunology . 2008 Nov;125(3):344–58. doi: 10.1111/j.1365-2567.2008.02849.x
Wu K, Yang Y, Liu D, Qi Y, Zhang C, Zhao J, et al. Activation of PPARγ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway. Oncotarget . 2016 Jul 12;7(28):44572–82. doi: 10.18632/oncotarget.10067
Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel J-F, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology . 2003 May;124(5):1265–76.
Dasu MR, Park S, Devaraj S, Jialal I. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology . 2009 Aug;150(8):3457–64. doi: 10.1210/en.2008-1757
Chistyakov D V., Aleshin S, Sergeeva MG, Reiser G. Regulation of peroxisome proliferator-activated receptor β/δ expression and activity levels by toll-like receptor agonists and MAP kinase inhibitors in rat astrocytes. Journal of Neurochemistry . 2014 Aug;130(4):563–74. doi: 10.1111/jnc.12757
Appel S, Mirakaj V, Bringmann A, Weck MM, Grünebach F, Brossart P. PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood . 2005 Dec 1;106(12):3888–94. doi: 10.1182/blood-2004-12-4709
Dana N, Haghjooy Javanmard S, Vaseghi G. The effect of fenofibrate, a PPARα activator on toll-like receptor-4 signal transduction in melanoma both in vitro and in vivo. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico . 2019 Jun 7. doi: 10.1007/s12094-019-02150-7
Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Current protocols in immunology . 2001 May;Chapter 20:Unit 20.1. doi: 10.1002/0471142735.im2001s39
Jensen MM, Jørgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC medical imaging . 2008 Oct 16;8:16. doi: 10.1186/1471-2342-8-16
Bundscherer A, Reichle A, Hafner C, Meyer S, Vogt T. Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists. Anti-Cancer Agents in Medicinal Chemistry . 2009 Sep 1;9(7):816–21. doi: 10.2174/187152009789056912
Skrypnyk N, Chen X, Hu W, Su Y, Mont S, Yang S, et al. PPARα activation can help prevent and treat non-small cell lung cancer. Cancer research . 2014 Jan 15;74(2):621–31.
Zhu B, Ferry CH, Blazanin N, Bility MT, Khozoie C, Kang B-H, et al. PPARβ/δ promotes HRAS-induced senescence and tumor suppression by potentiating p-ERK and repressing p-AKT signaling. Oncogene . 2014 Nov 13;33(46):5348–59. doi: 10.1038/onc.2013.477.
Tachibana K, Yamasaki D, Ishimoto K, Doi T. The Role of PPARs in Cancer. PPAR Research . 2008;2008:1–15. doi: 10.1155/2008/102737
Cao L-Q, Shao Z-L, Liang H-H, Zhang D-W, Yang X-W, Jiang X-F, et al. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression. Cancer letters . 2015 Apr 1;359(1):127–35. doi: 10.1016/j.canlet.2015.01.004
Cho S-J, Kook M-C, Lee JH, Shin J-Y, Park J, Bae Y-K, et al. Peroxisome proliferator-activated receptor γ upregulates galectin-9 and predicts prognosis in intestinal-type gastric cancer. International journal of cancer . 2015 Feb 15;136(4):810–20. doi: 10.1002/ijc.29056
Bolden A, Bernard L, Jones D, Akinyeke T, Stewart L V. The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells. PPAR research . 2012;2012:929052. doi: 10.1155/2012/929052
Chen X, Chang L, Qu Y, Liang J, Jin W, Xia X. Tea polyphenols inhibit the proliferation, migration, and invasion of melanoma cells through the down-regulation of TLR4. International journal of immunopathology and pharmacology . 2018;32:394632017739531. doi: 10.1177/0394632017739531
Sertznig P, Reichrath J. Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise. Dermato-endocrinology . 2011 Jul;3(3):130–5. doi: 10.4161/derm.3.3.15025
Freudlsperger C, Schumacher U, Reinert S, Hoffmann J. The Critical Role of PPARgamma in Human Malignant Melanoma. PPAR research . 2008;2008:503797. doi: 10.1155/2008/503797
Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer research . 2007 Nov 1;67(21):10519–27. doi: 10.1158/0008-5472.CAN-07-0079
Dengfeng G, Meng Z, Liu Z, Dong X, Dengfeng G. GW25-e5248 PPARγ agonist Pioglitazone Suppresses AngII-induced Inflammation in Cardiac Fibroblast Cells via TLR4-depended Signaling Pathway. Journal of the American College of Cardiology . 2014 Oct;64(16):C13–4. doi: 10.1016/j.jacc.2014.06.071
Yin Y, Hou G, Li E, Wang Q, Kang J. PPARγ agonists regulate tobacco smoke-induced Toll like receptor 4 expression in alveolar macrophages. Respiratory research . 2014 Mar 11;15:28. doi: 10.1186/1465-9921-15-28
Eun CS, Han DS, Lee SH, Paik CH, Chung YW, Lee J, et al. Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway. Digestive diseases and sciences . 2006 Apr;51(4):693–7. doi: 10.1007/s10620-006-3193-0
Wang C-Z, Zhang Y, Li X-D, Hu Y, Fang Z-G, Lin D-J, et al. PPARγ Agonist Suppresses TLR4 Expression and TNF-α Production in LPS Stimulated Monocyte Leukemia Cells. Cell Biochemistry and Biophysics . 2011 Jul 23;60(3):167–72. doi: 10.1007/s12013-010-9136-6
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Journal of Pharmacy & Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.
CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.
